Humacyte, Inc., a clinical‑stage regenerative medicine company, announced that its bioengineered human vessel, branded as Symvess, has received Emergency Care Applied Technology (ECAT) designation from the U.S. Defense Logistics Agency.
According to the company, Symvess is a universally implantable, off‑the‑shelf vascular conduit derived from human cells and developed for urgent vascular repair and trauma situations, particularly in military and civilian settings. The company said that this designation adds Symvess to the ECAT catalogue, which streamlines procurement for the U.S. Department of Defense, Veterans Affairs, and other federal agencies.
The company claims Symvess offers advantages over traditional synthetic grafts and vein harvesting, especially in contaminated wounds where infection risk is high. It is decellularized to minimize immune response and is intended for immediate availability without the need for patient‑matched tissue.
Humacyte stated that the ECAT listing follows regulatory milestones including FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, as well as Breakthrough Device designation. The company added that Symvess is currently under FDA review for potential use in urgent vascular repair in trauma and has been evaluated in both civilian clinical studies and preclinical military trauma models.
